Hydroxyurea trial aims to stop strokes in african kids with sickle cell

NCT ID NCT06526117

Recruiting now Prevention Sponsor: Vanderbilt University Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether hydroxyurea, a drug already used for sickle cell disease, can prevent strokes in 220 high-risk children in Nigeria. Children with sickle cell anemia and abnormal blood flow in the brain will receive low then moderate doses of hydroxyurea. The goal is to see if this treatment reduces stroke or mini-stroke rates in real-world clinics.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Hydroxyurea (a drug that helps reduce sickle cell complications)
What this could lead to: If successful, this could provide a simple, low-cost way to prevent strokes in children with sickle cell disease in Africa, where resources are limited.
What could go wrong: This is a single-arm trial (no comparison group), so results may be less definitive. Hydroxyurea can cause side effects like low blood counts, and long-term benefits are not yet proven in this setting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sickle cell disease stroke disorder prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SICKLE CELL DISEASE STROKE

Contacts and locations

Locations

Aminu Kano Teaching Hospital
RECRUITING

Kano, Nigeria
Murtala Muhammad Specialist Hospital
RECRUITING

Kano, Nigeria

More trials for these conditions

Other studies related to the condition(s) this trial covers.